Looking just at the 50mg $MRK gefapixant data, the 37% was the lowest out of the measured timepoints (wks 4, 8, 12). While wk 12 was the primary endpoint, for comparative purposes to $BLU, I'm not sure anchoring to this 37% is fair. Here's some other efficacy data as well: